Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Investment analysts at Oppenheimer Holdings issued their Q3 2018 EPS estimates for shares of Vanda Pharmaceuticals in a note issued to investors on Monday. Oppenheimer Holdings analyst D. Archila expects that the biopharmaceutical company will post earnings of $0.03 per share for the quarter. Oppenheimer Holdings has a “Buy” rating and a $21.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ Q4 2018 earnings at $0.09 EPS and FY2021 earnings at $1.16 EPS.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The company had revenue of $42.06 million during the quarter, compared to the consensus estimate of $40.31 million. During the same period in the previous year, the company posted $0.01 EPS. The firm’s revenue was up 16.7% on a year-over-year basis. ILLEGAL ACTIVITY NOTICE: This article was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.themarketsdaily.com/2017/10/12/q3-2018-earnings-forecast-for-vanda-pharmaceuticals-inc-issued-by-oppenheimer-holdings-vnda.html.
Other analysts have also issued reports about the company. Piper Jaffray Companies set a $23.00 target price on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. HC Wainwright set a $18.00 target price on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Jefferies Group LLC reaffirmed a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. BidaskClub raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. Finally, Zacks Investment Research lowered Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $21.29.
Vanda Pharmaceuticals (NASDAQ VNDA) traded up 0.62% on Wednesday, reaching $16.35. The company had a trading volume of 241,853 shares. The stock’s market capitalization is $733.43 million. Vanda Pharmaceuticals has a 1-year low of $12.70 and a 1-year high of $18.99. The stock’s 50 day moving average is $17.46 and its 200-day moving average is $15.62.
A number of institutional investors and hedge funds have recently modified their holdings of VNDA. Virginia Retirement Systems ET AL acquired a new stake in Vanda Pharmaceuticals in the first quarter valued at approximately $193,000. Prudential Financial Inc. grew its holdings in Vanda Pharmaceuticals by 0.8% in the first quarter. Prudential Financial Inc. now owns 614,318 shares of the biopharmaceutical company’s stock valued at $8,600,000 after purchasing an additional 4,700 shares during the period. American International Group Inc. grew its holdings in Vanda Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after purchasing an additional 1,491 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Vanda Pharmaceuticals in the first quarter valued at approximately $196,000. Finally, FMR LLC grew its holdings in Vanda Pharmaceuticals by 60.7% in the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock valued at $22,416,000 after purchasing an additional 604,900 shares during the period. 86.49% of the stock is currently owned by institutional investors.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.